Dose-response effects of tiagabine on the sleep of older adults

Sleep

Volumn 28, Issue 6, 2005, Pages 673-676

  Walsh, James K ^a,b,d   Randazzo, Angela C ^a   Frankowski, Sara ^c   Shannon, Kathy ^c   Schweitzer, Paula K ^a   Roth, Thomas ^c  

^a ST LUKE S HOSPITAL   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d Sleep Medicine and Research Center   (United States)

Author keywords

Dose response; Elderly; Sleep maintenance; Slow wave sleep; Tiagabine; Wake after sleep onset

Indexed keywords

TIAGABINE;

ADULT; AGE; AGED; AROUSAL; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; HUMAN EXPERIMENT; LATIN SQUARE DESIGN; MALE; NORMAL HUMAN; PERFORMANCE; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; SLEEP TIME; SLOW WAVE SLEEP; WAKEFULNESS;

EID: 20444371312     PISSN: 01618105     EISSN: None     Source Type: Journal    
DOI: 10.1093/sleep/28.6.673     Document Type: Article

References (18)

1. Lancel M, Faulhaber J, Deisz RA. Effect of the GABA uptake inhibitor tiagabine on sleep and EEG power spectra in the rat. Br J Pharmacol 1998;123:1471-7.
2. Mathias S, Wetter TC, Steiger A, et al. The GABA uptake inhibitor tiagabine promotes slow wave sleep in normal elderly subjects. Neurobiol Aging 2001;22:247-53.
3. Taylor FB. Tiagabine for posttraumatic stress disorder: a case series of 7 women. J Clin Psychiatry 2003;64:1421-5.
4. Rosenthal M. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 2003;64:1245-9.
5. Fink-Jensen A, Suzdak PD, Swedberg MD, et al. The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur J Pharmacol 1992;220:197-201.
6. Borden LA, Murali Dhar TG, Smith KE, et al. Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol 1994;269:219-24.
7. Carskadon MA, Rechtschaffen A. Monitoring and staging human sleep. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine, 3rd ed. Philadelphia: WB Saunders; 1994:943-60.
8. Rechtschaffen A, Kales A. A Manual of Standardized Terminology, Techniques, and Scoring System for Sleep Stages in Human Subjects. Washington: US Government Printing Office; 1968.
9. Roehrs T, Bonahoom A, Pedrosi B, et al. Disturbed sleep predicts hypnotic self-administration. Sleep Med 2002;3:61-6.
10. Reynolds CF III, Kupfer DJ, Taska LS, et al. Sleep of healthy seniors: a revisit. Sleep 1985;8:20-9.
11. Zammit GK, McNabb LJ, Caron J, et al. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004;20:1979-91.
12. Scharf MB, Roth T, Vogel GW, Walsh JK. A multi-center, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994;55:192-9.
13. Walsh JK, Fry J, Erwin CW, Scharf M, Roth T, Vogel GW. Efficacy and safety of 14-day administration of zaleplon 5 mg and 10 mg for the treatment of primary insomnia. Clin Drug Invest 1998;16:347-54.
14. Brunner DP, Dijk DJ, Borbely AA. Repeated partial sleep deprivation progressively changes the EEG during sleep and wakefulness. Sleep 1993;16:100-13.
15. Mullaney DJ, Johnson LC, Naitoh P, et al. Sleep during and after gradual sleep reduction. Psychophysiology 1977;14:237-44.
16. Webb WB, Agnew HW Jr. Sleep: Effects of a restricted regime. Science 1965;150:1745-7.
17. Ambrosini MV, Giuditta A. Learning and sleep: the sequential hypothesis. Sleep Med Rev 2001;5:477-90
18. Edinger JD, Glenn DM, Bastian LA, et al. Slow-wave sleep and waking cognitive performance II: Findings among middle-aged adults with and without insomnia complaints. Physiol Behav 2000;70:127-34.